RxDoctor Payments Data

Gregory Walker, MD

Internal Medicine · Baltimore, MDNPI 1366508301

Payments from drug & device makers

$11,599in general payments, 2019–2025

Across 424 payments — averaging $27.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$2K
  • Mallinckrodt Hospital Products Inc.$878
  • Johnson & Johnson$676
  • Viiv Healthcare Company$561
  • Kowa Pharmaceuticals America, Inc.$503
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$11,42298%
  • Education$1772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,599 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$48,314
Medicare patients
60
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi14$52,738
EliquisApixaban25$21,290
EntrestoSacubitril/Valsartan17$16,568
OzempicSemaglutide14$15,497
JardianceEmpagliflozin12$10,800
OxycontinOxycodone Hcl11$6,413
Soliqua 100-33Insulin Glargine/Lixisenatide20$3,899
Oxycodone Hcl124$2,874
FingolimodFingolimod Hcl11$2,332
Nifedipine ErNifedipine14$1,432
Ventolin HfaAlbuterol Sulfate15$1,320
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,177
Albuterol Sulfate HfaAlbuterol Sulfate33$1,026
Sumatriptan11$979
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq$561$52,73814 claims
PfizerEliquis$240$21,29025 claims
NovartisEntresto$416$16,56817 claims
Novo NordiskOzempic$439$15,49714 claims
Boehringer IngelheimJardiance$113$10,80012 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$194$3,89920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →